76,968 Shares in Bristol Myers Squibb Company $BMY Bought by Asset One Wealth Management LLC

Key Points

• Asset One Wealth Management purchased 76,968 Bristol Myers Squibb shares worth approximately $4.52 million, while institutional investors collectively own 76.41% of the company.
• Analyst sentiment is broadly positive: BMY has a “Moderate Buy” consensus rating and a $66.06 average price target, with recent upgrades from Weiss Ratings and Sanford C. Bernstein.
• Bristol Myers Squibb beat quarterly earnings and revenue estimates, reported 5.7% year-over-year revenue growth, and maintains a quarterly dividend of $0.63, yielding about 3.8%. Generic competition affecting legacy products remains a key risk.

Asset One Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 76,968 shares of the biopharmaceutical company's stock, valued at approximately $4,520,000.

A number of other large investors have also recently made changes to their positions in BMY. Swiss RE Ltd. purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $25,000. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter worth $25,000. Physician Wealth Advisors Inc. boosted its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 202 shares during the last quarter. Davis Asset Management L.P. bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth $27,000. Finally, Bayban purchased a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $31,000. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Weiss Ratings upgraded shares of Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, August 18th. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research note on Wednesday, August 5th. Royal Bank Of Canada lifted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a "sector perform" rating in a research report on Friday, July 31st. Truist Financial restated a "buy" rating and issued a $70.00 target price (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, BMO Capital Markets reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of "Moderate Buy" and a consensus price target of $66.06.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $67.06 on Monday. The company has a market capitalization of $136.98 billion, a PE ratio of 14.77, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $68.64. The company has a 50-day simple moving average of $60.55 and a 200 day simple moving average of $59.39.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. Bristol Myers Squibb's quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's payout ratio is currently 55.51%.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source